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ABSTRACT—Neonatal sepsis is one of the most fulminating conditions in neonatal intensive care units. Antipathogen and
supportive care are administered routinely, but do not deliver satisfactory results. In addition, the efforts to treat neonatal
sepsis with anti-inflammatory agents have generally shown to be futile. The accumulating data imply that intracellular redox
changes intertwined into neonatal sepsis redox cycle represent the main cause of dysfunction of mitochondria and cells in
neonatal sepsis. Our aim here is to support the new philosophy in neonatal sepsis treatment, which involves the integration
of mechanisms that are responsible for cellular dysfunction and organ failure, the recognition of the most important targets,
and the selection of safe agents that can stop the neonatal sepsis redox cycle by hitting the hot spots. Redox-active agents
that could be beneficial for neonatal sepsis treatment according to these criteria include lactoferrin, interleukin 10, zinc and
selenium supplements, ibuprofen, edaravone, and pentoxifylline.
KEYWORDS—Antioxidants, mitochondria, neonate, oxidative stress, sepsis
ABBREVIATIONS—GSH V glutathione; GPx V glutathione peroxidase; H2O2 V hydrogen peroxide; iNOS V inducible
nitric oxide synthase; NF-.BV nuclear factor .B; NICUV neonatal intensive care unit; &O2
jV superoxide radical anion;
ONOOjV peroxynitrite
INTRODUCTION
The treatment of critically ill neonates is particularly sensitive
issue because neonatal sepsis is one of the most fulminating
conditions in neonatal intensive care units (NICUs) that places
an immense emotional burden and pressure on parents, physi-
cians, and society. So, it is no wonder that current strategies in
neonatal sepsis treatment are focused on pathogen eradication by
an early application of empirical combination of narrow-
spectrum antibiotics (1). Despite the guidelines, the reserve
broad-spectrum antibiotics are often used for the empirical
therapy of neonatal sepsis. Unfortunately, such approach de-
livers results that are far from satisfactory and encounters dif-
ferent setbacks perpetually. Broad-spectrum antibiotics exert
selective pressure on specific bacterial species, which might
promote the growth of some other bacteria or could leave eco-
logical niche wide open for fungi. For example, the efforts to
reduce the rate of group B streptococcus disease using intre-
partum antimicrobial prophylaxis have been associated with
increased rates of gram-negative infections (2). The incidence of
neonatal sepsis caused by fungal infections has increased sev-
eral folds in developed countries in the past two decades (3, 4),
whereas the incidence of invasive candidiasis correlates with
average per-infant use of broad-spectrum antibiotics (5). Fur-
thermore, almost any NICU or country might find itself from
time to time in a position to deal with the outbreaks of strains
resistant to antibiotics that are routinely applied in accordance to
the clinical practice or national authority’s recommendations
(6, 7). Antibiotic-resistant strains still represent a problem in low-
and middle-income countries, related to the challenges of access
(a limited number of antibiotics is available) and excess (the use
of antibiotics is poorly controlled) (8). Finally, the regimens for
neonatal sepsis treatment currently recommended by national
pediatric associations do not adequately account for coagulase-
negative Staphylococcus (9). This might be the cause of rising
incidence of coagulase-negative StaphylococcusYcaused neonatal
sepsis in developed countries (3, 4).
Another general problem is the lack of clinical studies in neo-
nates, which significantly affects efficacy, safety, and the quality
of therapy. The majority of antibiotics and 90% of other drugs
prescribed in NICUs are used in off-label and unlicensed manner
(10, 11). The use of drugs based on extrapolated results obtained
in infants, children, and adult population has generally been in-
adequate because of the significant pharmacokinetic and phar-
macodynamic differences (12). The lack of pharmacokinetic and
pharmacodynamic data for antibiotics used in neonates increases
the risk of overdosing and subdosing, adverse effects and/or in-
efficacy, and rapid development of resistance (13, 14). Clinical
assessments of the current antibiotics as well as the development
of new drugs, designed on the basis of pathophysiological char-
acteristics of disease in neonates, are imperative for efficient and
safe therapy for neonatal sepsis (15, 16).
179
SHOCK, Vol. 42, No. 3, pp. 179Y184, 2014
Address reprint requests to Ivan Spasojevi(, PhD, Institute for Multidisciplinary
Research, University of Belgrade, Kneza Vixeslava 1, 11030 Belgrade, Serbia. E-mail:
redoxsci@gmail.com
This study was supported by the Ministry of Education and Science of the
Republic of Serbia (grant OI173014 BMolecular Mechanisms of Redox Signaling in
Homeostasis, Adaptation and Pathology[ and grant 43004).
Conflicts of interest and source of funding: none declared.
DOI: 10.1097/SHK.0000000000000198
Copyright  2014 by the Shock Society
Copyright © 2014 by the Shock Society. Unauthorized reproduction of this article is prohibited.
NEONATAL SEPSIS REDOX CYCLE
In two recent editorials reflecting on yet another failure of an
anti-inflammatory agent to treat sepsis, the authors concluded that
BThis setback should inspire a redoubling of efforts to seek new
approaches to treatment that are based on a more crystalline view
of the biology of sepsis[ (17), and BIn the end, however, a single
cure for sepsis seems unlikely. A deeper understanding of the
processes leading to sepsis is necessary before we can design an
effective suite of interventions[ (18). So, in parallel to day-to-day
fighting, we ought to look at what has been done in the field of
the pathophysiology of neonatal sepsis in order to explore new
treatment possibilities. And this is by no means little, as the focus
has moved considerably in the past decade from the immune
system activity to intracellular redox changes. Previously ac-
cepted hypothesis that (neonatal) sepsis is in fact an uncontrolled
inflammatory response (19) has faced the Bwall[ of unsuccessful
trials (20, 21). It turned out that, during the course of sepsis
progression, immune system shows not one but two drastically
different phases: hyperactive and hypoactive (20). Furthermore,
some phenomena, such as negative blood cultures, which are
frequently confirmed in sepsis patients (22, 23), and sporadic
cases of sepsis provoked by pathogen-unrelated insults (24), im-
ply that, like inflammation, the infection itself might only repre-
sent a step in the initiation of sepsis mechanisms that thereafter
act independently of inflammation or the type of pathogen and
are ubiquitous to all sepsis patients. A new player emerged on the
scene in 2001 (although it was first proposed in 1995 by Vlessis
and colleagues [25]), when Fink (26) postulated that dysfunc-
tional mitochondria and redox changes are to be blamed for organ
failure in sepsis. Since then, accumulating data increased the
awareness of scientific community that redox processes taking
place in the intracellular compartment, and mitochondria in par-
ticular, have an essential role in the pathogenesis of sepsis
(27Y30). We have recently integrated the state-of-the-art knowl-
edge on neonatal and adult sepsis in order to postulate that a self-
sustaining and self-promoting (neonatal) Bsepsis redox cycle[ is
initiated in the intracellular compartment (Fig. 1), resulting in
mitochondria, cell, and eventually organ dysfunction (27, 28). In
brief, the Bcycle[ in neonatal cells sets off with interleukins (IL-6
and IL-8)Ymediated activation of nuclear factor .B (NF-.B),
which regulates the expression of inducible nitric oxide (NO) syn-
thase (iNOS). High concentrations of NO inhibit electron transport
chain, resulting in increased production of superoxide radical anion
(&O2
j) and hydrogen peroxide (H2O2) in mitochondria (31, 32).
Hydrogen peroxide from mitochondria further activates NF-.B,
which results in the development of self-sustaining/promoting
loop leading to mitochondria dysfunction, energy failure, and
cellular dysfunction. The Bcycle[ is additionally supported by
NF-.BYactivated expression of cyclooxygenase 2, which has
&O2
j as a by-product. Superoxide is dismutated to H2O2, both in
mitochondria and cytoplasm. In mitochondria, &O2
j reacts with
NO to produce peroxynitrite (ONOOj). Peroxynitrite inhibits
glutathione (GSH) reductase, which is coupled with GSH per-
oxidase (GPx), the key enzyme for H2O2 removal in mitochon-
dria. In addition, ONOOj can be decomposed to two very
harmful speciesVhydroxyl and nitrogen dioxide radical. NO and
H2O2 can leak from the cell in order to activate neonatal sepsis
redox cycle in surrounding tissue. There are several key differ-
ences in the redox signaling and redox-mediated cellular/tissue
FIG. 1. Neonatal sepsis redox cycle, redox-active agents and their targets in neonatal sepsis treatment. Neonatal sepsis redox cycle is presented in full
lines (+ promotion/increase; - inhibition/decrease). The effects of agents on specific targets in neonatal sepsis redox cycle are presented with dashed lines.
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damage that clearly delineate neonatal sepsis as a separate entity
from adult sepsis: (i) immature innate immune system in neonates
shows low capacity to generate reactive oxygen species (33), so
pro-oxidative processes in neonatal sepsis are generally limited to
intracellular compartment of affected tissues. (ii) Neonatal cells
regulate the level of H2O2 via GPx, whereas adult cells generally
use catalase. As an illustration, GPx activity is twofold to sixfold
higher, whereas catalase activity is threefold lower in neonatal
tissues compared with adults (34). (iii) Neonatal cells appear to
compensate for sepsis-provoked mitochondrial dysfunction by
extramitochondrial ATP production (35), which is not the case in
adult tissues (36). (iv) Proliferating cells are particularly suscep-
tible to apoptosis that can be initiated by oxidative stress (28). In
relation to this, neonatal sepsis-related cellular dysfunction might
result in devastating effects in developing tissues, such as brain
(periventricular leukomalacia, intraventricular hemorrhage, cere-
bral palsy, vision impairments), lungs (respiratory distress syn-
drome and bronchopulmonary dysplasia), and heart (patent
ductus arteriosus) (37, 38). In contrast, adult sepsis provokes re-
versible changes or minor damage (39, 40). This explains a
considerably higher incidence of long-term effects in neonatal
sepsis survivors (41) compared with adults (42), but also points
out the importance of redox therapy in neonatal sepsis treatment.
TARGETS AND STRATEGY OF REDOX THERAPY
Redox-active molecules form a complex, intertwined system in
neonatal sepsis that cannot be repaired by a blunt application of
unspecific antioxidants hoping that they will do well, which has
often been the case in animal studies and even some clinical trials.
This is probably one of the reasons why believable benefit from
application of some antioxidants has not been translated into suc-
cess in human clinical trials (43Y45). Instead, redox approach
should target specific steps in the pathogenesis of neonatal sepsis.
A plausible agent should be capable of entering and accumulating
in the intracellular compartment and mitochondria of affected
tissues. This is not an easy task because cells comprise a refractory
system in order to tightly control the intracellular level of reducing
species (e.g., vitamins C and E), which is essential for maintaining
a balanced redox poise and normal redox signaling (46). The ap-
plication of preferentially extracellular redox-active agents might
be futile, whereas prophylactic application of such agents could
even show negative effects in neonates. Pertinent to the former,
we have recently shown that redox settings in the blood of septic
neonates are no different compared with matching controls (47).
Based on this, it was proposed that the application of vitamin E in
septic neonates might not be rational. Even more, one Cochrane
study documented that prophylactic vitamin E significantly in-
creases the risk of sepsis in neonates (48). This could be explained
by the direct scavenging activity of vitamin E and its ability to
increase the capacity of neonatal erythrocytes to remove reactive
oxygen species, which are used by the innate immune system to
kill pathogens (47). In this way, already weak neonatal immune
system might be further compromised. However, some extracel-
lular agents could still find a place in neonatal sepsis prophylaxis.
The availability of iron plays an important role in sepsis because
iron is obligatory for proliferation of bacteria. Hence, the se-
questration of iron in plasma should decrease the number of
pathogens (49). Iron-removing strategy might be particularly im-
portant in newborns, because their system of iron regulation is
immature; i.e., they show low levels of transferrin and cerulo-
plasmin (50). Lactoferrin is the only iron-sequestering agent that
is tested in clinical trials on neonates. One study on 472 very low-
birth-weight neonates showed that lactoferrin substantially re-
duces the incidence of both bacterial and fungal sepsis (51), and
there are several ongoing multicenter studies further examining
this issue. It is worth mentioning that observational studies imply
that breast milk, which contains lactoferrin and reduces the
growth of Escherichia coli and other gram-negative pathogenic
bacteria, has an impact on infection-specific mortality rates during
neonatal period (52). We have described recently a unique
antioxidative profile of breast milk, which might be relevant for its
beneficial effects in neonates exposed to infection (53).
PROMISING REDOX-ACTIVE AGENTS
The strategy of drug development for the treatment of neo-
natal sepsis is based on the evaluation of the existing drugs and
the development of new drugs for unique pathophysiological
processes characteristic for neonates. Child health is a priority
for European Commission (EC), as illustrated by the topic in the
very first FP7 callVBPaediatric Medical Products: Adapting Off
Patient Medicines to the Specific Needs of Paediatric
Populations,[ as well as by TINN (Treat Infections in Neonates)
programs, which are founded in order to evaluate anti-infective
drugs (ciprofloxacin, fluconazole, and azithromycin) in neo-
nates. These drugs are prescribed off-label to treat life-
threatening neonatal infections. Apart from neonatal clinical
drug evaluations, this research also contains in silico experi-
ments and animal studies and evaluates formulations adapted to
neonates. Modeled on these EC programs, the incitement of the
neonatal evaluations of existing promising redox-active drugs,
as well as the development of the new ones based on the
knowledge of sepsis mechanisms including neonatal sepsis re-
dox cycle, would certainly contribute to the significant im-
provement of therapy of neonatal sepsis.
The available data on redox therapy for neonatal sepsis are
rather limited. For example, a brief systematic search of PubMed
(electronic database of the US National Library of Medicine) for
articles that contain the term neonatal sepsis, word therapy or
treatment, and one of the following words: redox, antioxidant,
and antioxidative, returned only some 100 results. Nevertheless,
there is a small set of promising and generally safe agents that
could be applied in the treatment of neonatal sepsis. Several
agents can be used to suppress the first step in neonatal sepsis
redox cycle: NF-.BYinduced gene expression (Fig. 1). For ex-
ample, Mittal and coworkers (54) have recently proposed that
low-quantity IL-10 would be beneficial in the treatment of neo-
nates with meningitis, based on the results showing that IL-10
prevents infection-related brain damage and decreases the mor-
tality rate in model animals infected even with antibiotic-resistant
strains. Interleukin 10 is known to inhibit NF-.B expression (55)
and the transduction of extracellular inflammatory stimuli to in-
tracellular production of reactive species (56). In a recent clinical
trial, the supplementation of zinc (Zn) in infants aged between 7
and 120 days with probable serious bacterial infection resulted in
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significantly fewer treatment failures compared with placebo
group (57). Such positive effects could be at least partially
attributed to Zn-provoked inhibition of NF-.B in vital organs
(58, 59) and potentially to direct effects of Zn on some pathogens
(60). It is worth mentioning that oral Zn supplementation given at
high doses reduces morbidities (including sepsis-related) and
mortality in preterm neonates (61). Ibuprofen decreased the level
of IL-6 and C-reactive protein in septic neonates and attenuated
lethality of neonatal sepsis in model animals (62). The beneficial
effects of ibuprofen could be at least partially attributed to its
capacity to abrogate NF-.B, iNOS, and cyclooxygenase 2 ac-
tivity (63). It is noteworthy that ibuprofen represents a reasonably
effective drug for patent ductus arteriosus closure in neonates
(64). Edaravone (3-methyl-1-phenyl-pyrazolin-5-one), a relatively
novel free radical scavenger on the market, has been shown to
prolong the survival of septic newborn piglets (65). In sepsis
models, edaravone inhibited the activation of NF-.B, reduced the
induction of iNOS, and decreased NO production (65, 66). A
more recent study found that edaravone might inhibit the induc-
tion of iNOS gene expression in an NF-.BYindependent manner
(67). There are no data on the safety of edaravone in neonates,
but it has been approved by Japanese regulatory authorities for
clinical use in the management of acute ischemic stroke. It
should be stressed that NF-.B inhibitors generally should not be
applied in the prophylaxis of neonatal sepsis, as they might
suppress reactive species-generating activity of immune system
cells (68), thus leaving neonates more susceptible to infections.
A novel approach in antioxidative therapy is to target oxidative
changes in mitochondria in order to preserve/regain their function,
which is disrupted in neonatal sepsis. Two principal strategies for
antioxidative protection of mitochondria have been postulated by
Galley (29): (i) the application of radical scavengers that are de-
livered specifically to mitochondria (lipophilic cations, Tempol-
conjugates, specific bioactive peptides) and (ii) the amplification of
endogenous mitochondrial antioxidative protection, for example,
via pharmacological upregulation of the GSH system. There are
two promising agents that could mediate beneficial effects in
neonatal sepsis via the GSH system, whereas data on other ap-
proaches of mitochondria-targeting redox therapy in neonatal
sepsis are still awaited. Two randomized controlled trials enrolling
140 neonates with suspected/confirmed sepsis showed that xan-
thine derivative, pentoxifylline, significantly reduces mortality rate
(69). Pentoxifylline restores GSH level and preserves viability of
mitochondria showing inhibited respiration (70). The other agent is
selenium (Se), which is essential for de novo synthesis of GPx (71).
A Cochrane study found that the supplementation of Se is associ-
ated with significant reduction of neonatal sepsis incidence (72).
Premature newborns are often Se deficient, and early Se supple-
mentation appears to be very important for preventing and treating
sepsis in this group (73). There are some other strategies that could
be tested on animal models for neonatal sepsis. Molecular hydro-
gen (H2), a small gaseous reducing agent, is known to alleviate
intracellular oxidative stress (74). The inhalation with 2% H2 im-
proved the survival rate of adult septic mice in a concentration- and
time-dependent manner (75, 76). It appears important to examine a
potential link between the ability of intestinal bacteria to produce
H2 (77) and the effects of probiotics on sepsis and some other
conditions in neonates (78). Finally, intracellular antioxidative
system can be upregulated by promoting nuclear factor E2Yrelated
factor (Nrf2)Ydependent transcription of antioxidative enzymes:
NAD(P)H:quinine oxidoreductase 1 and GSH-related enzymes.
This can be achieved by the application of thiol-binding agents,
which stabilize Nrf2 or modify the Nrf2 inhibitor, Kelch-like ECH-
associated protein 1 (79). One agent that has the ability to activate
Nrf2 and has been tested in adult sepsis is ethyl pyruvate (80). A
potential problem with the application of this strategy in neonatal
sepsis might be the suppression of the immune system via cell-
surface thiol redox-switches modulation (81).
CONCLUSIONS
Neonatal sepsis still represents an immense problem in NICUs
around the world, having the potential to escalate in the future
because of the rise of antibiotic-resistant strains and fungal
infections. Something has to be done to supplement current
approach, save lives, and alleviate social and emotional bur-
den. Our aim was to point out the new philosophy in neonatal
sepsis treatment, which involves: (i) integrative approach on
the mechanismsVneonatal sepsis redox cycle, resulting in cellu-
lar dysfunction and organ failure; (ii) recognition of the most
important targets; and (iii) the selection of safe, low-cost agents
that can stop the neonatal sepsis redox cycle. The redox therapy
could show the best results if agents with different targets are
applied in combination. As we noted previously, there is no
Bmagic bullet[ for sepsis treatment, but Bmagic bullets[ are re-
quired instead. Further research and trials are needed, but it is
important that we at least partially redirect our efforts toward
testing available and developing new redox (antioxidative) agents
in order to arrest the process of neonatal sepsis.
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